You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Focal Tumour Ablation: Transarterial Chemoembolization for Hepatocellular Carcinoma

ID: FA 2 Mar 2015
Type of Content: Guidelines & Advice, Evidence Summary
Document Status: In-Review
A. Ménard, F.G. Baldassarre, G. Martel, J. Kachura, Focal Ablation Advisory Committee

Guideline Objective

To provide a systematic literature review that will be one of the six components of the Recommendation Report (i.e., demand forecasting, costing analysis, jurisdictional review, literature review, system capacity, and current state) of the Focal Ablation Advisory Committee.

Patient Population

Patients with HCC.

Intended Guideline Users

Interventional radiologists, radiation oncologists, hepatobiliary surgeons, medical oncologists, healthcare professionals caring for patients with HCC or colorectal liver metastases.

Research Question(s)

  1. What is the effectiveness of transarterial chemoembolization (TACE) for the treatment of patients with hepatocellular carcinoma (HCC)?
    • What is the side effect profile and treatment outcome of conventional TACE versus drug-eluting bead TACE (DEB-TACE)?
  2. What patient populations are most likely to benefit from TACE?
  3. Is there a difference in any important outcomes when performing TACE as an inpatient or an outpatient procedure?